Multiple Myeloma

A clinically meaningful 40% overall response rate was seen in a subset of patients with triple class refractory multiple myeloma who received CLR 131 at a total administered dose of 60 mCi or greater.

The new drug application is seeking approval for the treatment of adult patients with multiple myeloma whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD-38 monoclonal antibody.

The FDA approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy.

The FDA approved the first anti-BCMA therapy, belantamab mafodotin-blmf, to treat patients with relapsed/refractory multiple myeloma who have received 4 prior therapies.

The study is evaluating the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone as treatment for patients with relapsed or refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discussed second malignancies and second transplants for patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.

The committee voted 12-0 in favor of the demonstrated benefit of belantamab mafodotin as monotherapy outweighing the risks for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on clinical hold following the submission of a patient’s safety report.

However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient population, regardless of CHIP status.

Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma.

Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.

The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma.

CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.

Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated  in patients with heavily pretreated relapsed or refractory multiple myeloma.

The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.

The hematologist and medical oncologist discussed the approval of daratumumab and hyaluronidase-fihj for use in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.

The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.

Karyopharm Therapeutics announced plans to commence a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19.

A case study of a patient in Wuhan, China demonstrated that tocilizumab may be an effective treatment for very ill patients with COVID-19 who also have multiple myeloma and other blood cancers.

Researchers indicated that these results show the feasibility of this regimen and support the development of additional studies of melflufen in multiple myeloma, both in combination with dexamethasone as well as in triplet regimens.

ONCOLOGY recently sat down with Kenneth C. Anderson, MD, to discuss the current trends in multiple myeloma treatment, and the explosion of novel therapies that are paving the way to better and more durable outcomes and allowing patients to live longer and more meaningful lives.

The FDA approved isatuximab-irfc, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor.

The Mayo Clinic expert spoke about stem cell transplantation for patients with myeloma and the factors that affect the ability to collect stem cells.

The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.

The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.

The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them.

In a workshop conducted by the FDA and AACR, researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications.